FDA clears new platform for AI heart assessments | Big news for Mount Sinai | Surgeons share their perspective

An updated version of Heartflow's Plaque Analysis platform has gained FDA clearance. In addition, the company announced that Cigna will cover the platform going forward.

Jamieson M. Bourque, MD, MHS, previewed his plans for the future in a new interview with Cardiovascular Business. 

AI-powered chatbots can be valuable resources when users have questions about cardiovascular health—but they are still far from perfect.

Mount Sinai Fuster Heart Hospital aims to take its use of AI during interventional procedures to the next level and find new ways to transform patient care. 

The algorithm, trained on more than 150,000 TTE studies, can calculate 18 different measurements regularly used in echocardiography

Evaluating LVDF with echocardiography or AI-powered electrocardiography can help identify individuals at an increased risk of developing atrial fibrillation, according to new data presented at the ASE 36th Annual Scientific Sessions.

Cardiac surgeons see significant value in AI's ability to assist clinicians with administrative tasks and patient selection. When it comes to making clinical decisions, however, there is still a certain amount of skepticism. 

The Tempus Pixel platform was designed to assist clinicians with the evaluation of cardiac MR images.